Immunoglobulin Market Size to Hit US$ US$ 24.9 Billion by 2032 | Grow CAGR by 5.1%
Immunoglobulin Market Size to Hit US$ US$ 24.9 Billion by 2032 | Grow CAGR by 5.1%
UNITED STATES, July 17, 2024 /EINPresswire.com/ -- IMARC Groupโs report titled "๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐ ๐ฅ๐จ๐๐ฎ๐ฅ๐ข๐ง ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ฒ ๐๐ซ๐จ๐๐ฎ๐๐ญ (๐๐ ๐, ๐๐ ๐, ๐๐ ๐, ๐๐ ๐, ๐๐ ๐), ๐๐ฉ๐ฉ๐ฅ๐ข๐๐๐ญ๐ข๐จ๐ง (๐๐ฒ๐ฉ๐จ๐ ๐๐ฆ๐ฆ๐๐ ๐ฅ๐จ๐๐ฎ๐ฅ๐ข๐ง๐๐ฆ๐ข๐, ๐๐ก๐ซ๐จ๐ง๐ข๐ ๐๐ง๐๐ฅ๐๐ฆ๐ฆ๐๐ญ๐จ๐ซ๐ฒ ๐๐๐ฆ๐ฒ๐๐ฅ๐ข๐ง๐๐ญ๐ข๐ง๐ ๐๐จ๐ฅ๐ฒ๐ง๐๐ฎ๐ซ๐จ๐ฉ๐๐ญ๐ก๐ฒ (๐๐๐๐), ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐๐๐๐ข๐๐ข๐๐ง๐๐ฒ ๐๐ข๐ฌ๐๐๐ฌ๐, ๐๐ฒ๐๐ฌ๐ญ๐ก๐๐ง๐ข๐ ๐๐ซ๐๐ฏ๐ข๐ฌ, ๐๐ง๐ ๐๐ญ๐ก๐๐ซ๐ฌ), ๐๐จ๐๐ ๐จ๐ ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฒ (๐๐ง๐ญ๐ซ๐๐ฏ๐๐ง๐จ๐ฎ๐ฌ ๐๐จ๐๐ ๐จ๐ ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฒ, ๐๐ฎ๐๐๐ฎ๐ญ๐๐ง๐๐จ๐ฎ๐ฌ ๐๐จ๐๐ ๐จ๐ ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฒ), ๐๐ง๐ ๐๐๐ ๐ข๐จ๐ง ๐๐๐๐-๐๐๐๐". The global immunoglobulin market size reached US$ 15.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
๐๐ซ๐๐ ๐ ๐ฌ๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐จ๐ ๐ญ๐ก๐ข๐ฌ ๐ซ๐๐ฉ๐จ๐ซ๐ญ: https://www.imarcgroup.com/immunoglobulin-market/requestsample
๐ ๐๐๐ญ๐จ๐ซ๐ฌ ๐๐๐๐๐๐ญ๐ข๐ง๐ ๐ญ๐ก๐ ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐จ๐ ๐ญ๐ก๐ ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐ ๐ฅ๐จ๐๐ฎ๐ฅ๐ข๐ง ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ:
โ ๐๐ง๐๐ซ๐๐๐ฌ๐ข๐ง๐ ๐๐ซ๐๐ฏ๐๐ฅ๐๐ง๐๐ ๐จ๐ ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐๐๐๐ข๐๐ข๐๐ง๐๐ฒ ๐๐ง๐ ๐๐ฎ๐ญ๐จ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ ๐๐ข๐ฌ๐จ๐ซ๐๐๐ซ๐ฌ:
The rising prevalence of immunodeficiency and autoimmune disorders among the masses across the globe is propelling the market growth. Conditions like primary immunodeficiency diseases (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), and autoimmune diseases necessitate regular administration of immunoglobulin therapies to manage symptoms and enhance patient quality of life. These therapies are essential for increasing the immune system's function, particularly in individuals with compromised immune responses. In addition, the growing awareness among individuals about the diagnosis of these conditions is positively influencing the marketโโ. ย ย ย ย
โ ๐๐๐ฏ๐๐ง๐๐๐ฆ๐๐ง๐ญ๐ฌ ๐ข๐ง ๐๐ข๐จ๐ญ๐๐๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐๐ง๐ ๐๐๐ง๐ฎ๐๐๐๐ญ๐ฎ๐ซ๐ข๐ง๐ ๐๐ซ๐จ๐๐๐ฌ๐ฌ๐๐ฌ:
Innovations in biotechnology and manufacturing processes have revolutionized the immunoglobulin market. Enhanced purification techniques and innovative production methods assist in improving the safety and efficacy of immunoglobulin products. These advancements allow for higher yields and purer products, reducing the risk of adverse reactions. Innovations, such as subcutaneous immunoglobulins (SCIG), provide more convenient and patient-friendly treatment options, allowing for home-based administration and improved adherence to therapy. The ongoing research and development (R&D) efforts in this field are continually introducing better formulations and delivery methodsโ.
โ ๐๐ง๐๐ซ๐๐๐ฌ๐ข๐ง๐ ๐๐๐จ๐ฉ๐ญ๐ข๐จ๐ง ๐จ๐ ๐๐ฎ๐๐๐ฎ๐ญ๐๐ง๐๐จ๐ฎ๐ฌ ๐๐๐ฆ๐ข๐ง๐ข๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง:
The rising adoption of subcutaneous administration (SCIG) of immunoglobulins due to its convenience and effectiveness is bolstering the market growth. SCIG allows patients to self-administer treatments at home, which reduces the need for frequent hospital visits and provides flexibility in dosing schedules. This method improves patient quality of life and treatment adherence, as it is less invasive and can be managed independently. Increasing preferences for SCIG over traditional intravenous methods on account of its associated benefits, including reduced infusion times, fewer side effects, and the ability to maintain more stable blood levels of immunoglobulins, is impelling the market growth.
๐๐ฌ๐ค ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ญ ๐๐จ๐ซ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ:ย https://www.imarcgroup.com/request?type=report&id=4505&flag=C
๐๐๐๐๐ข๐ง๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ ๐๐ฉ๐๐ซ๐๐ญ๐ข๐ง๐ ๐ข๐ง ๐ญ๐ก๐ ๐๐ฅ๐จ๐๐๐ฅ ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐ ๐ฅ๐จ๐๐ฎ๐ฅ๐ข๐ง ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ:
โ ADMA Biologics Inc.
โ Baxter international Inc.
โ Biotest AG, CSL Limited
โ Grifols S.A
โ Kedrion S.p.A
โ LFB SA
โ Octapharma AG
โ Sanquin Plasma Products B.V.
โ Takeda Pharmaceutical Company Limited.
๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐ ๐ฅ๐จ๐๐ฎ๐ฅ๐ข๐ง ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง:
๐๐ฒ ๐๐ซ๐จ๐๐ฎ๐๐ญ:
โ IgG
โ IgA
โ IgM
โ IgE
โ IgD
IgG represents the largest segment as it plays a critical role in the immune response and defense against pathogens. ย ย
๐๐ฒ ๐๐ฉ๐ฉ๐ฅ๐ข๐๐๐ญ๐ข๐จ๐ง:
โ Hypogammaglobulinemia
โ Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
โ Immunodeficiency Disease
โ Myasthenia Gravis
โ Others
Immunodeficiency disease holds the biggest market share due to its essential role in immunoglobulin therapy. ย
๐๐ฒ ๐๐จ๐๐ ๐จ๐ ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฒ:
โ Intravenous Mode of Delivery
โ Subcutaneous Mode of Delivery
Intravenous mode of delivery accounts for the largest market share, driven by its rapid and efficient absorption.ย ย
๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ:
โ North America (United States, Canada)
โ Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
โ Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
โ Latin America (Brazil, Mexico, Others)
โ Middle East and Africa
North America enjoys a leading position in the immunoglobulin market on account of the presence of robust healthcare infrastructure with state-of-the-art medical facilities and technologies. ย
๐๐ฅ๐จ๐๐๐ฅ ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐ ๐ฅ๐จ๐๐ฎ๐ฅ๐ข๐ง ๐๐๐ซ๐ค๐๐ญ ๐๐ซ๐๐ง๐๐ฌ:
The growing demand for immunoglobulin among the geriatric population, as they are more susceptible to immunodeficiency and autoimmune conditions, is offering a favorable market outlook. This demographic shift leads to a higher prevalence of diseases, such as pelvic inflammatory disease (PID) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), among individuals, which necessitates regular and effective immunoglobulin treatments to manage their health.
Governing agencies of various countries are providing more approvals for new immunoglobulin products, facilitating quicker market entry. In addition, they are funding and supporting research and development (R&D) efforts, which is impelling the market growth.ย ย
๐๐จ๐ญ๐: ๐๐ ๐ฒ๐จ๐ฎ ๐ง๐๐๐ ๐ฌ๐ฉ๐๐๐ข๐๐ข๐ ๐ข๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง ๐ญ๐ก๐๐ญ ๐ข๐ฌ ๐ง๐จ๐ญ ๐๐ฎ๐ซ๐ซ๐๐ง๐ญ๐ฅ๐ฒ ๐ฐ๐ข๐ญ๐ก๐ข๐ง ๐ญ๐ก๐ ๐ฌ๐๐จ๐ฉ๐ ๐จ๐ ๐ญ๐ก๐ ๐ซ๐๐ฉ๐จ๐ซ๐ญ, ๐ฐ๐ ๐ฐ๐ข๐ฅ๐ฅ ๐ฉ๐ซ๐จ๐ฏ๐ข๐๐ ๐ข๐ญ ๐ญ๐จ ๐ฒ๐จ๐ฎ ๐๐ฌ ๐ ๐ฉ๐๐ซ๐ญ ๐จ๐ ๐ญ๐ก๐ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐๐ญ๐ข๐จ๐ง.
๐๐ญ๐ก๐๐ซ ๐๐๐ฅ๐๐ญ๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐ฒ ๐๐๐๐๐ ๐๐ซ๐จ๐ฎ๐ฉ
๐๐๐ ๐๐จ๐ง๐ญ๐ซ๐๐๐ญ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ ๐๐ง๐ ๐๐๐ง๐ฎ๐๐๐๐ญ๐ฎ๐ซ๐ข๐ง๐ ๐๐ซ๐ ๐๐ง๐ข๐ณ๐๐ญ๐ข๐จ๐ง๐ฌ ๐๐๐ซ๐ค๐๐ญ: https://www.imarcgroup.com/aav-contract-development-manufacturing-organizations-market
๐๐ง๐ข๐ฆ๐๐ฅ ๐ ๐๐๐ ๐๐ซ๐ ๐๐ง๐ข๐ ๐๐ซ๐๐๐ ๐๐ข๐ง๐๐ซ๐๐ฅ๐ฌ ๐๐๐ซ๐ค๐๐ญ: https://www.imarcgroup.com/animal-feed-organic-trace-minerals-market
๐๐จ๐ซ๐ญ๐ข๐ ๐๐๐ฅ๐ฏ๐ ๐๐๐ฉ๐ฅ๐๐๐๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ: https://www.imarcgroup.com/aortic-valve-replacement-market
๐๐๐จ๐ฎ๐ญ ๐๐ฌ
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Groupโs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companyโs expertise.
Elena Anderson
IMARC Services Private Limited
+ +1 631-791-1145
email us here
![](https://www.einpresswire.com/tracking/article.gif?t=4&a=eHDZYHDhVxTmdmxU&i=svsdfQjq372KSqYC)